¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦71Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ : 2019-04-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦71Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ : 2019-04-17
±³À°ÀÏÀÚ : 2019-04-17
±³À°Àå¼Ò : ÀüÁÖ ±×·£µåÈú½ºÅÏÈ£ÅÚ ±×·¹À̽ºÈ¦ ¿Ü 3°³·ë  
±³À°ÁÖÁ¦ : Á¦71Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
´ã´çÀÚ : ±èÀ¯Âù
¿¬¶ôó : 02-3473-0284  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 700¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : Àü¶óºÏµµ
±³À°½Ã°£ : 21 ½Ã°£ 8ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í Á¤È¸¿ø »çÀü70,000/ÇöÀå80,000, ÁØȸ¿ø »çÀü30,000/ÇöÀå40,000, ¸¸65¼¼ ÀÌ»ó ¸éÁ¦, ºñȸ¿ø 50,0000      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 04-17 ±×·¹À̽º 13:35~13:40 Introduction: Memorial lecture  Chair() 
±³À°½Ã°£ 04-17 ±×·¹À̽º 13:40~13:55 Epigenetic regulation in skin aging  À̵¿ÈÆ(¼­¿ïÀÇ´ë) 
Åä·Ð 04-17 ±×·¹À̽º 13:55~14:00 Q&A  () 
±âŸ 04-17 ±×·¹À̽º 13:15~13:20 Introduction  Chair() 
±³À°½Ã°£ 04-17 ±×·¹À̽º 13:20~13:35 Robotic hair transplantation  °­±¤¿µ(¸ð·¡³»ÇǺΰú) 
±âŸ 04-17 ±×·¹À̽º 14:00~14:05 Introduction  Chair() 
±³À°½Ã°£ 04-17 ±×·¹À̽º 14:05~14:50 Rosacea: our inquiry epidemiology to microbiome  Sewon Kang(Department of Dermatology, Johns Hopkins School of Medicine, USA) 
Åä·Ð 04-17 ±×·¹À̽º 14:50~15:00 Q&A  () 
±âŸ 04-17 ±×·¹À̽º 15:30~15:35 Introduction  Chair() 
±³À°½Ã°£ 04-17 ±×·¹À̽º 15:35~16:20 Photodynamic therapy for MRSA and pseudomonas-infected skin ulcer  Daisuke Tsuruta(Department of Dermatology, Osaka City University, Japan) 
Åä·Ð 04-17 ±×·¹À̽º 16:20~16:30 Q&A  () 
±âŸ 04-17 ±×·¹À̽º 16:30~16:35 Introduction  Chair() 
±³À°½Ã°£ 04-17 ±×·¹À̽º 16:35~17:20 Immunotherapy for melanoma: Present and future  Xiaowei Xu(Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, USA) 
Åä·Ð 04-17 ±×·¹À̽º 17:20~17:30 Q&A  () 
±âŸ 04-17 µ¥ÀÌÁö½º 15:30~15:33 Overview  ±è¼öÂù(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 15:33~15:52 Ichthyoses  ±è¼öÂù(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 15:52~16:11 Updated classification and therapeutic challenges of epidermolysis bullosa  ÀÌ»óÀº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 16:11~16:30 Genetic role in skin cancer development  ¹ÚÁöÇý(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 16:30~16:49 Human genome and genomic testing in clinical practice  À¯ÇÑ¿í(¼­¿ï¾Æ»êº´¿ø ÀÇÇÐÀ¯ÀüÇм¾ÅÍ) 
Åä·Ð 04-17 µ¥ÀÌÁö½º 16:49~17:00 Q&A  () 
±³À°½Ã°£ 04-17 ±×·¹À̽º 09:30~09:54 What''s new in dermatology drugs  ÀÌ°©¼®(Áß¾ÓÀÇ´ë) 
Åä·Ð 04-17 ±×·¹À̽º 09:54~10:00 Q&A  () 
±³À°½Ã°£ 04-17 ±×·¹À̽º 10:00~10:20 Update on publication ethics  Çѵ¿¼ö(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-17 ±×·¹À̽º 10:20~10:40 Conflict of interest  ±è¼ö¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04-17 ±×·¹À̽º 10:40~11:00 Personal data protection (publication consent)  ÀÌÀº¼Ò(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-17 ±×·¹À̽º 11:00~11:20 Reporting guidelines  ³ëÁÖ¿µ(°¡ÃµÀÇ´ë) 
Åä·Ð 04-17 ±×·¹À̽º 11:20~11:30 Q&A  () 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 17:30~17:52 How to claim insurance on dermatologic field  È²Ã¶(´ëÀü¿À¶óŬÇǺΰú) 
Åä·Ð 04-17 ±×·£µåº§¶ó 17:52~18:00 Q&A  () 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 18:00~18:22 How to treat onychomycosis using pinpoint laser without oral drug  È²Ã¶(´ëÀü¿À¶óŬÇǺΰú) 
Åä·Ð 04-17 ±×·£µåº§¶ó 18:22~18:30 Q&A  () 
±âŸ 04-17 µ¥ÀÌÁö½º 14:00~14:03 Introduction  Chair() 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 14:03~14:53 Success ÀλóÇР ÁÖ¼±Èñ(¿ø±¤µðÁöÅдëÇб³ ¾ó±¼°æ¿µÇаúÀå) 
Åä·Ð 04-17 µ¥ÀÌÁö½º 14:53~15:00 Q&A  () 
±âŸ 04-17 ±×·£µåº§¶ó 15:30~15:33 Introduction  Chair() 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 15:33~16:23 ÇÁ·¹Á¨Å×ÀÌ¼Ç Æ®·»µå¿Í ÃֽŠÆÄ¿öÆ÷ÀÎÆ® È°¿ë¹ý  À̱¤Èñ(´õÇÇóÇÇƼ ´ëÇ¥) 
Åä·Ð 04-17 ±×·£µåº§¶ó 16:23~16:30 Q&A  () 
±âŸ 04-17 ±×·£µåº§¶ó 16:30~16:33 Introduction  Chair() 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 16:33~17:23 ¸¶À½À» ¿òÁ÷ÀÌ´Â ¸»°ú ±Û  °­¿ø±¹(ÀüºÏ´ë Ãʺù±³¼ö) 
Åä·Ð 04-17 ±×·£µåº§¶ó 17:23~17:30 Q&A  () 
±³À°½Ã°£ 04-17 ±×·¹À̽º 17:30~18:17 Dermatoses by Mite and Tick  Á¶¹é±â(°¡Å縯ÀÇ´ë) 
Åä·Ð 04-17 ±×·¹À̽º 18:17~18:30 Q&A  () 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 09:30~09:40 Á¶Á÷°Ë»ç, ¸é¿ªÇü±¤°Ë»ç  ¹ÚÁؼö(´ë±¸°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 09:40~09:50 Áø±Õ  ÀÌÁöÇö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 09:50~10:00 ±¤°Ë»ç  ±èÁ¤¼ö(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 10:00~10:10 Ã¸Æ÷°Ë»ç  ÀÌ°¡¿µ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 10:10~10:20 ¾Ë·¹¸£±â  °íÇöâ(ºÎ»êÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 10:20~10:30 ´õ¸ð½ºÄÚÇÇ  ¹®Á¦È£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 10:30~10:42 ½ºÅ×·ÎÀ̵堠±è¸í½Å(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 10:42~10:54 Ç×Áø±Õ/Ç×»ý  ¹ÚÁø(ÀüºÏÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 10:54~11:06 ¸é¿ª¾ïÁ¦Á¦  Á¤º¸¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 11:06~11:18 ·¹Æ¼³ëÀ̵堠Àå¿ëÇö(°æºÏÀÇ´ë) 
±³À°½Ã°£ 04-17 µ¥ÀÌÁö½º 11:18~11:30 Ç×È÷½ºÅ¸¹ÎÁ¦  ¿À»óÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 09:30~09:45 Laser basics & tissue interaction  ÃÖ¿µÁØ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 09:45~10:00 Safety related regulation  À¯È­Á¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 10:00~10:15 Practical way to protect skin, eye and airway during laser surgery  ±èÇý¼º(°¡Å縯ÀÇ´ë) 
Åä·Ð 04-17 ±×·£µåº§¶ó 10:15~10:30 Q&A  () 
±³À°½Ã°£ 04-17 ±×·¹À̽º 11:30~12:15 Recent update on sCHE and Alitretinoin  Alexandra Marta(GSK) 
Åä·Ð 04-17 ±×·¹À̽º 12:15~12:20 Q&A  () 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 10:30~11:15 Complete clearance, new treatment goal with Ixekizumab  Prof. Yayoi Tada(Jichi medical University) 
Åä·Ð 04-17 ±×·£µåº§¶ó 11:15~11:30 Q&A  () 
±³À°½Ã°£ 04-17 ±×·£µåº§¶ó 14:00~14:45 Korean guideline for the treatment of onychomycosis and newer topical agent  ¹ÚÁø(ÀüºÏÀÇ´ë) 
Åä·Ð 04-17 ±×·£µåº§¶ó 14:45~15:00 Q&A  () 
±âŸ 04-17 ¼¼ÀÎÆ® 14:00~14:05 Overview  chair() 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 14:05~14:20 The associated skin diseases and comorbid allergic diseases  ³ëÁÖ¿µ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 14:20~14:35 The psychosocial co-morbidities  ½Å¹Î°æ(°æÈñÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 14:35~14:50 The systemic co-morbidities  À̾ç¿ø(°Ç±¹ÀÇ´ë) 
Åä·Ð 04-17 ¼¼ÀÎÆ® 14:50~15:00 Q&A  () 
±âŸ 04-17 ¼¼ÀÎÆ® 15:30~15:35 Overview  chair() 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 15:35~15:47 Upstream regulation: IL-23  ±èµ¿Çö(Â÷ÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 15:47~15:58 Downstream regulation: IL-17  ½ÅºÀ¼®(Á¶¼±ÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 15:58~16:09 Resident memory T cell in psoriasis  ³ªÁ¤ÀÓ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 16:09~16:20 Skin & intestinal microbiomes in psoriasis  Á¤±âÇå(°æÈñÀÇ´ë) 
Åä·Ð 04-17 ¼¼ÀÎÆ® 16:20~16:30 Q&A  () 
±âŸ 04-17 ¼¼ÀÎÆ® 16:30~16:35 Overview  ³ëÁÖ¿µ(°¡ÃµÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 16:35~16:50 Pruritus: pathogenesis  ±èÇý¿ø(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 16:50~17:05 Management: conventional - antihistamines  Áֹμ÷(Áß¾Óº¸Èƺ´¿ø) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 17:05~17:20 Management: new treatment paradigm  ÀÌÁöÇö(°¡Å縯ÀÇ´ë) 
Åä·Ð 04-17 ¼¼ÀÎÆ® 17:20~17:30 Q&A  () 
±âŸ 04-17 ¼¼ÀÎÆ® 17:30~17:35 Overview  chair() 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 17:35~17:50 Underlying mechanism of wrinkles as a major feature of photoaging  Á¤ÁøÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 17:50~18:05 Underlying mechanism of dyspigmentation as another bothersome problem of photoaging  °­Èñ¿µ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-17 ¼¼ÀÎÆ® 18:05~18:20 Emerging treatment and promising treatment targets for skin photoaging  Ã̶ֹó(ÀÎÁ¦ÀÇ´ë) 
Åä·Ð 04-17 ¼¼ÀÎÆ® 18:20~18:30 Q&A  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦71Â÷ ´ëÇÑÇǺΰúÇÐȸ Ãá°èÇмú´ëȸ : 2019-04-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇѽŰæ¿Ü°úÇÐȸ Á¦37Â÷ Ãá°èÇмú´ëȸ_1st Day : 2019-04-18
´ÙÀ½±Û 2019 ´ëÇÑ°¡Á¤ÀÇÇÐȸ ÃæºÏÁöȸ Ãá°èÇмú´ëȸ : 2019-04-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20898 °æ±â ¿ëÀμ¼ºê¶õ½ºº´¿ø µðÁöÅÐÀÇ·á½ÉÆ÷Áö¾ö -¹Ì·¡ ÀǷḦ À§ÇÑ ±³·ù¿Í Çù·Â : 2024-07-04 0 15 2024-05-28
20897 ¼­¿ï ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ ENDO 2024 (Day1) : 2024-07-04 0 10 2024-05-28
20896 ¼­¿ï ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­ºÎÁöȸ Á¤±â Áý´ãȸ(Àڱ󻸷Áõ½ÄÁõ) : 2024-07-02 0 14 2024-05-28
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 12 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 31 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 121 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 42 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 121 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 34 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 23 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 24 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 44 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 13 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 21 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 12 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷